NASDAQ: QNCXQuince Therapeutics Inc Stock
$1.11+0.05 (+4.72%)
Updated Apr 23, 2024
QNCX Price
$1.11
Fair Value Price
$1.73
Market Cap
$47.97M
52 Week Low
$0.84
52 Week High
$1.74
P/E
-1.32x
P/B
0.56x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$31.39M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.97
Operating Cash Flow
-$18M
Beta
1.08
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
QNCX Overview
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how QNCX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
QNCX ($1.11) is undervalued by 35.86% relative to our estimate of its Fair Value price of $1.73 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
QNCX ($1.11) is significantly undervalued by 35.86% relative to our estimate of its Fair Value price of $1.73 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
QNCX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more QNCX due diligence checks available for Premium users.
Be the first to know about important QNCX news, forecast changes, insider trades & much more!
QNCX News
Valuation
QNCX fair value
Fair Value of QNCX stock based on Discounted Cash Flow (DCF)
Price
$1.11
Fair Value
$1.73
Undervalued by
35.86%
QNCX ($1.11) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
QNCX ($1.11) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
QNCX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
QNCX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.32x
Industry
16.46x
Market
41.92x
QNCX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.56x
Industry
5.93x
QNCX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
QNCX's financial health
Profit margin
Revenue
$0.0
Net Income
-$8.9M
Profit Margin
0%
QNCX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$167.9M
Liabilities
$82.8M
Debt to equity
0.97
QNCX's short-term assets ($77.44M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
QNCX's short-term assets ($77.44M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
QNCX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
QNCX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.1M
Investing
$5.4M
Financing
$57.0k
QNCX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
QNCX vs Biotech Stocks
Quince Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.